ARX788 in Breast Cancer With Low Expression of HER2

• ClinicalTrials.gov Identifier: NCT05018676
• Recruitment Status: Unknown
• First Posted: August 24, 2021
• Last Update Posted: April 25, 2022
• Sponsor: Fudan University
• Information provided by (Responsible Party): Xichun Hu, Fudan University

Study Description

Brief Summary:

A Phase 2 Study of ARX788 in unresectable and/or metastatic breast cancer with low expression of HER2.

Condition or disease	Intervention/treatment	Phase
Breast Cancer With Low Expression of HER2	Drug: ARX788	Phase 2

Detailed Description:

A single arm, phase 2 study of ARX788 in unresectable and/or metastatic breast cancer with low expression of HER2. Subjects should received ≥2 lines of systemic chemotherapy regimens for recurrent or metastatic disease, and for HR positive subjects, also need to have received ≥2-line endocrine therapy ± targeted therapy (including neoadjuvant/adjuvant therapy). HER2 low expression is defined as HER2 IHC 1+ or HER2 IHC 2+ and FISH negative. The ARX788 will be administered every 3 weeks (Q3W) intravenous (IV) infusion.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 54 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Single-arm, Single-center Phase II Clinical Study of Recombinant Humanized Anti-HER2 Monoclonal Antibody-AS269 Conjugate (ARX788) in the Treatment of Unresectable and/or Metastatic Breast Cancer With Low Expression of HER2
• Actual Study Start Date: October 20, 2021
• Estimated Primary Completion Date: December 30, 2022
• Estimated Study Completion Date: June 30, 2023

Arms and Interventions

Arm	Intervention/treatment
Experimental: ARX788	Drug: ARX788; 1.5 mgkg IV infusion on Day 1 of each 21-day treatment cycle.

Outcome Measures

Primary Outcome Measures :

1. Objective remission rate (ORR) [ Time Frame: 2 years ]
   ORR is defined as the percentage of subjects who have achieved complete response and partial response according RECIST 1.1

Secondary Outcome Measures :

1. Progression-free survival (PFS) [ Time Frame: 2 years ]
   PFS is defined as the time between date of first dose of study therapy and date of progression or death, whichever occurs first, will be computed for response evaluable subjects. Subjects will be censored at time of subsequent therapy
2. Overall survival (OS) [ Time Frame: 2 years ]
   Overall survival (OS) is defined as the time from first dose of study therapy to the date of death (any cause). Subjects who are alive will be censored at the last known time that the subject was alive
3. Disease control rate (DCR) [ Time Frame: 2 years ]
   Disease control rate (DCR) is defined as cases where objective remission (assessed as complete remission or partial remission according to RECIST 1.1 standard) or stable disease during the study
4. Duration of relief (DOR) [ Time Frame: 2 years ]
   DOR is defined as the time from the first documented objective response (CR or PR) to the first documented disease progression or death

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 75 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Willing and able to understand and sign an informed consent inform;
• Age ≥18 years, and ≤75 years, male or female;
• Diagnosed as HR arbitrary/HER2 low expression unresectable and/or metastatic breast cancer. HER2 low expression is defined as HER2 IHC 1+ (FISH negative or FISH not done) or HER2 IHC 2+ and FISH negative;
• Received ≥2 lines of systemic chemotherapy regimens for recurrent or metastatic disease, and for HR positive subjects, also need to have received ≥2-line endocrine therapy ± targeted therapy (including neoadjuvant/adjuvant therapy);
• Never had a HER2 positive result (IHC 3+ or FISH+) in previous pathological examinations;
• Have archived or fresh tumor tissue samples for HER2 status confirmation;
• According to the RECIST 1.1 standard, there is at least one measurable lesion;
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or1; LVEF≥50%;
• Adequate organ functions;
• Acute toxicities from any prior therapy, surgery, or radiotherapy must have resolved to Grade ≤1;
• Life expectancy ≥ 3 months.

Exclusion Criteria:

• History of allergic reactions to any component of ARX788, or with a history of protein drug allergy, a history of specific allergies (asthma, rheumatism, eczematous dermatitis), or a history of other severe allergic reactions, who are unsuitable for ARX788 treatment as per the investigator's judgments;
• Previous treatment with T-DM1 or other HER2-ADC drugs;
• Have other malignant tumors within 5 years before signing the informed consent form (except for non-melanoma skin cancer, cervical carcinoma in situ or other tumors that have been effectively treated, except malignant tumors that are considered cured);
• Have primary central nervous system (CNS) tumors or CNS metastases;
• Prior history of interstitial pulmonary disease requiring hormone therapy, drug-induced interstitial pulmonary disease, radiation pneumonia, or current clinically active interstitial pulmonary disease;
• Suffering from keratitis, corneal diseases, retinal diseases or active eye infections that require intervention;
• Unwilling or unable to stop wearing contact lenses for the duration of the study;
• Cardiac insufficiency;
• Uncontrolled hypertension;
• Suffering severe or uncontrolled systemic diseases;
• Had chemotherapy, radiotherapy, or immunotherapy within 4 weeks before the first dose;
• Had breast cancer endocrine therapy within 2 weeks before the first dose;
• Had palliative radiotherapy for bone metastasis within 2 weeks before the first dose;
• Any uncontrolled infection, or other conditions that may limit trial compliance or interfere with evaluation;
• Current known active infection with human immunodeficiency virus (HIV), hepatitis B virus, hepatitis C virus or syphilis;
• Plan to receive major surgical treatment within 2 weeks before first dose or during the trial period, or have suffered severe traumatic injury;
• Pregnancy or lactation;
• Unwilling or unable to use acceptable methods for contraception during the entire treatment period of this trial and within 8 months after the last dose;
• Participated in other clinical trials and used other experimental drugs within 4 weeks before the first dose;
• Any mental or cognitive impairment may limit their understanding and implementation of the informed consent form;
• Not suitable for participating in this trial, such as poor compliance.

Contacts and Locations

Contacts

Contact: Ting Li; +8618121299346; cinderellaliting@126.com

Locations

China

Fudan University Shanghai Cancer Center; Recruiting

Shanghai, China, 200032

Contact: Ting Li, M.D., Ph.D. 86-18121299346 cinderellaliting@126.com

Sponsors and Collaborators

Fudan University

More Information

• Responsible Party: Xichun Hu, Professor, Fudan University
• ClinicalTrials.gov Identifier: NCT05018676
• Other Study ID Numbers: ACE-Breast-07
• First Posted: August 24, 2021
• Last Update Posted: April 25, 2022
• Last Verified: April 2022

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Xichun Hu, Fudan University:

ARX788; Breast cancer; Low expression of HER2

Additional relevant MeSH terms:

Breast Neoplasms; Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases